ATNT-14PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA
نویسندگان
چکیده
منابع مشابه
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
BACKGROUND Angiogenesis inhibition is a rational treatment strategy for high-grade glioma (HGG). Combined antiangiogenic therapy and chemotherapy could be beneficial, taking advantage of different mechanisms of antitumour activity of both therapies. We carried out a phase I-II clinical trial with the combination of bevacizumab and continuous dose-intense temozolomide (TMZ) for patients with a r...
متن کاملAntiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
OBJECT Antiangiogenic agents have recently shown impressive radiological responses in high-grade glioma. However, it is not clear if the responses are related to vascular changes or due to antitumoral effects. The authors report the mature results of a clinical study of bevacizumab-based treatment of recurrent high-grade gliomas. METHODS Sixty-one patients with recurrent high-grade gliomas re...
متن کاملRe-Irradiation in Recurrent High-Grade Glioma
Background and Purpose: Despite the progress in treatment modalities such as neurosurgery and radiotherapy, almost all patients treated with malignant gliomas develop recurrent tumors and die of their disease. The aim of this study was to determine response, survival and treatment toxicities after reirradiation of relapsing primary malignant brain gliomas. Material and Methods: Twenty patients ...
متن کاملRapidArc: Initial experience in high grade glioma
Background: Identify the optimal technique of radiotherapy for patients with high grade glioma. Our initial year of experience with RapidArc radiation therapy. Materials and Methods: Planning CT scans of 50 patients with grade IV glioma were reviewed and three plan sets by 3D Conformal Radiotherapy (3DCRT), Intensity Modulated Radiotherapy (IMRT) and Rapid Arc (RA) were generated and the plans ...
متن کاملPhase I study of terameprocol in patients with recurrent high-grade glioma.
Terameprocol is a global transcription inhibitor that affects cell division apoptosis, drug resistance, hypoxia responsive genes, and radiation resistance in hypoxia. A multicenter, dose-escalation study was conducted in heavily pretreated patients with recurrent, measurable, high-grade gliomas. Terameprocol was administered intravenously for 5 consecutive days each month and discontinued for t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2015
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/nov205.14